Crispr Therapeutics AG

CRSP

NASDAQ. Currency in USD

44.06 -2.35 ( -5.06% )

Real time prices: December 19

Market Cap.
3.45B
Beta (5Y monthly)
1.70
Price/Earnings
-
EPS (TTM)
-8.80
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.16M
1y Target Est.
99.41
Day's Range
43.61
-
46.50
52 Week's Range
42.51
-
86.95

Historical Summary

Performance
EPS growth
Share Buybacks

About Crispr Therapeutics AG

Sector
Healthcare
Industry
Biotechnology
Website
https://www.crisprtx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
76.53M
Employees
473
Address
Baarerstrasse 14, Zug, Switzerland, 6300
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Latest news

2 Growth Stocks That Could Help Set You Up for Life
2 Growth Stocks That Could Help Set You Up for Life

Many growth stocks are down, but they're not all out.
By The Motley Fool - 8 weeks ago

5 Best Bargain Stocks to Buy Before 2023
5 Best Bargain Stocks to Buy Before 2023

It's time to hit the best sale in town, and that involves many top stocks.
By The Motley Fool - 8 weeks ago

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation

The three companies are changing the pharmaceutical industry.
By The Motley Fool - 8 weeks ago

Is CRISPR Therapeutics a Buy?
Is CRISPR Therapeutics a Buy?

A strong cash position could offset some of the near-term risks that come with owning...
By The Motley Fool - 8 weeks ago

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond

These biotech players beat the bear market this year.
By The Motley Fool - 8 weeks ago

3 Fierce Stocks That Are Screaming Buys in December
3 Fierce Stocks That Are Screaming Buys in December

Here are three winners in the making.
By The Motley Fool - 8 weeks ago

Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Is It Too Late to Buy Vertex Pharmaceuticals Stock?

The company has already made plenty of investors happy.
By The Motley Fool - 8 weeks ago

Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023
Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023

These top players are ripe for recovery -- and long-term growth.
By The Motley Fool - 8 weeks ago